» Advanced search
Only first 10,000 results will be saved in the file.
No item is selected. Use checkboxes to select search results.
Displaying 1-1 of 1 results.
 
{{ selectedCountPage }} items selected on this page, {{ selectedCountPage }} item selected on this page, {{ selectedCountTotal }} item in total {{ selectedCountTotal }} items in total
Study aim: Objective: evaluating the effect of total anthocyanin base standardized (cornus mas L.) fruit extract on liver function, tumor necrosis factor α, malondealdehyde and adiponectin in patients with non-alcoholic fatty liver (NAFLD). Design: Patients are randomly assigned into 2 groups (n=40 in each group) using a software to receive total anthocyanin base standardized (cornus mas L.) fruit extract (equal to 320 mg/d anthocyanins) or placebo daily for 12 weeks. Settings and conduct: In a randomized double-blind clinical trial, 80 patients with NAFLD will be recruited from Diabetes Research Center, Shahid Sadoughi university of medical sciences, Yazd. The subjects are randomly divided into two groups to take total anthocyanin base standardized (cornus mas L.) fruit extract or placebo. Participants/Inclusion and exclusion criteria: Study population: patients with NAFLD (n=80). Inclusion criteria: ALT levels more than 30 U / L in men and more than 19 U / L in women, age 25-26 years, the patients with grade 1, 2 and 3 fatty liver, the consent of subject to participate in the study, the patients are from Yazd. Exclusion criteria: The history of diseases including cirrhosis, viral hepatitis, cardiovascular disease, diabetes, Wilson and cancer; Consumption of medications including corticosteroids, nonsteroidal anti-inflammatory drugs, hypoglycemic agents, tamoxifen, sodium valproate, methotrexate, probiotics, any medicine or supplement that affect liver function, supplements with antioxidant and anti-inflammatory properties; Following a special diet; Pregnancy and breastfeeding; Alcohol consumption. Intervention groups: Intervention group with total anthocyanin base standardized (cornus mas L.) fruit extract or placebo group. Main outcome variables: Liver function (liver enzymes and cytokeratin-18 levels, liver steatosis and fibrosis); tumor necrosis factor α, malondealdehyde and adiponectin levels.
IRCTID: IRCT20180419039359N1
  1. The effect of vitamin D supplementation on serum hepatic enzymes, oxidative stress indicators & inflammatory markers in patients with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled trial
  2. The effect of hydro-alcoholic extract of Portulaca Oleracea L. (purslane) on Liver enzymes, Glycemic status and lipid profile in non-alcoholic fatty liver disease: a randomized, double-blind clinical trial.
  3. The effect of oral Chromium picolinate supplementation on Liver Function, Oxidative Indicators, Leptin, Resisten, lipid profile, Blood Glucose Control Indicators, serum levels of Fetuin A and inflammatory factors in Non-Alcoholic Fatty Liver
  4. Comparison of the effects of Camelina and Sunflower oils on metabolic, inflammatory and anti-inflammatory factors in patients with Non-alcoholic fatty liver
  5. The effect of Camelina oil with and without Resistant dextrin supplementation on metabolic, inflammatory and anti-inflammatory markers in patients with Non-alcoholic fatty liver
  6. The clinical trial of effects of nanocurcumin supplementation on blood nesfatin, insulin resistance indexes, lipids and inflammatory factors in overweight and obese patients with non-alcoholic fatty liver disease ‎‎(NAFLD)‎
  7. Effect of Calcitriol supplementation on the severity of fatty liver, inflammatory and metabolic biomarkers in patients with non-alcoholic fatty liver with different genotypes of vitamin D receptor
  8. Impact of curcumin capsules on serum levels of pro-inflammatory,anti-inflammatory cytokines and cell adhesion molecules in Non-alcoholic fatty liver disease
  9. Evaluation of the effects of Cornus Mas L. fruit extract capsule on blood glucose and HgbA1C in patients with type 2 diabetes mellitus
  10. Effect of green coffee extract supplementation on metabolic status, serum leptin level and anthropometric measurements in patients with non-alcoholic fatty liver disease
Loading...